The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Zhang Q, Delessa CT, Augustin R, Bakhti M, Colldén G, Drucker DJ, Feuchtinger A, Caceres CG, Grandl G, Harger A, Herzig S, Hofmann S, Holleman CL, Jastroch M, Keipert S, Kleinert M, Knerr PJ, Kulaj K, Legutko B, Lickert H, Liu X, Luippold G, Lutter D, Malogajski E, Medina MT, Mowery SA, Blutke A, Perez-Tilve D, Salinno C, Sehrer L, DiMarchi RD, Tschöp MH, Stemmer K, Finan B, Wolfrum C, Müller TD. · 2021
Read The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. by Zhang Q, Delessa CT, Augustin R, Bakhti M, Colldén G, Drucker DJ, Feuchtinger A, Caceres CG, Grandl G, Harger A, Herzig S, Hofmann S, Holleman CL, Jastroch M, Keipert S, Kleinert M, Knerr PJ, Kulaj K, Legutko B, Lickert H, Liu X, Luippold G, Lutter D, Malogajski E, Medina MT, Mowery SA, Blutke A, Perez-Tilve D, Salinno C, Sehrer L, DiMarchi RD, Tschöp MH, Stemmer K, Finan B, Wolfrum C, Müller TD. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8035082.txt.
Introduction
Zhang and co-authors show that a gut hormone receptor in the brain controls body weight and food intake. The hormone GIP acts on the pancreas, but whether its receptor should be switched on or off for obesity was unclear. The receptor also sits in hypothalamic feeding centers. The team deleted it from the brain in mice, including a humanized strain. The animals ate a high-fat diet.
Brain-receptor knockout mice gained less weight and handled glucose better. Giving acyl-GIP, centrally or peripherally, cut food intake and weight in normal mice. The effect vanished in mice lacking the brain receptor. The extra benefit of combined GLP-1 and GIP treatment also disappeared. The authors conclude that the brain receptor is the key control point.
Catalog record
| CREATOR | Zhang Q, Delessa CT, Augustin R, Bakhti M, Colldén G, Drucker DJ, Feuchtinger A, Caceres CG, Grandl G, Harger A, Herzig S, Hofmann S, Holleman CL, Jastroch M, Keipert S, Kleinert M, Knerr PJ, Kulaj K, Legutko B, Lickert H, Liu X, Luippold G, Lutter D, Malogajski E, Medina MT, Mowery SA, Blutke A, Perez-Tilve D, Salinno C, Sehrer L, DiMarchi RD, Tschöp MH, Stemmer K, Finan B, Wolfrum C, Müller TD. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling By Qian Zhang, Challa Tenagne Delessa, Robert Augustin, Mostafa Bakhti, Gustav Colldén, Daniel J. Drucker, Annette Feuchtinger, Cristina Garcia Caceres, Gerald Grandl, Alexandra Harger, Stephan Herzig, Susanna Hofmann Published in: Cell Metabolism DOI: 10.1016/j.cmet.2021.01.015 ABSTRACT Summary Uncertainty exists as to whether the glucose-dependent insulinotropic polypeptide receptor (GIPR) should be activated or inhibited for the treatment of obesity. Gipr was recently demonstrated in hypothalamic feeding centers, but the physiological relevance of CNS Gipr remains unknown. Here we show that HFD-fed CNS-Gipr KO mice and humanized (h)GIPR knockin mice with CNS-hGIPR deletion show decreased body weight and improved glucose metabolism. In DIO mice, acute central and peripheral administration of acyl-GIP increases cFos neuronal activity in hypothalamic feeding centers, and this coincides with decreased body weight and food intake and improved glucose handling. Chronic central and peripheral administration of acyl-GIP lowers body weight and food intake in wild-type mice, but shows blunted/absent efficacy in CNS-Gipr KO mice. Also, the superior metabolic effect of GLP-1/GIP co-agonism relative to GLP-1 is extinguished in CNS-Gipr KO mice. Our data hence establish a key role of CNS Gipr for control of energy metabolism. INTRODUCTION The glucose-dependent insulinotropic polypeptide (GIP) regulates blood glucose via its insulinotropic and glucagonotropic action on the pancreas (Christensen et al., 2011; Finan et al., 2016). While the glycemic effects of GIP receptor (GIPR) agonism are solidly confirmed, uncertainty exists as to whether GIPR should be stimulated or inhibited for the treatment of type 2 diabetes mellitus (T2DM) and obesity (Holst and Rosenkilde, 2020). Global germline Gipr knockout (KO) mice show lower body weight and preserved insulin sensitivity upon high-fat diet (HFD) feeding (Miyawaki et al., 2002), and the insulinotropic response to GIP is impaired in patients with T2DM (Nauck et al., 1993). GIP activates lipoprotein lipase (Eckel et al., 1979; Kim et al., 2007, 2010), stimulates uptake of fatty acids and glucose (Beck and Max, 1986; Hauner et al., 1988), and promotes lipid synthesis in cultured adipocytes (Hauner et al., 1988). These data align with studies in humans, in which GIP is shown to promote lipid storage by increasing adipose tissue blood flow and triglyceride uptake (Asmar et al., 2017). These and other data have spurred the development of GIPR antagonists for the treatment of T2DM and obesity. Recently, it was shown that GIPR antagonizing antibodies improve body weight and glucose control in mice and non-human primates (Killion et al., 2018) and enhance the anorectic effect of leptin in HFD-fed mice (Kaneko et al., 2019). In contrast to these data, overexpression of Gip improves body weight and glycemia in HFD-fed mice (Kim et al., 2012). Pigs expressing a dominant-negative Gipr in the β cells are glucose intolerant and show reduced glucose stimulation of insulin secretion (Renner et al., 2010). Optimized GIP analogs decrease body weight in wild-type (WT) and GLP-1 receptor (GLP-1R) KO mice, but fail to do so in mice deficient for Gipr (Mroz et al., 2019). Co-administration of a GLP-1R agonist with a GIPR agonist synergistically decreases body weight and fat mass in diet-induced obese (DIO) mice (Finan et al., 2013). Unimolecular dual-agonists targeting the receptors for GLP-1 and GIP decrease body weight and improve glucose handling in animal models of obesity and T2DM (Coskun et al., 2018; Finan et al., 2013), non-human primates (Finan et al., 2013), and obese patients with T2DM (Coskun et al., 2018; Finan et al., 2013; Frias et al., 2018). Moreover, the dual-agonists exhibit greater efficacy relative to GLP-1R agonism alone in preclinical studies (Coskun et al., 2018; Finan et al., 2013) and clinical trials (Frias et al., 2018). In summary, there is considerable uncertainty as to how GIPR agonism versus antagonism improves energy metabolism. Expression of Gipr was recently demonstrated in cells/neurons of the arcuate (ARC), dorsomedial (DMH), and paraventricular (PVH) nuclei of the hypothalamus, and Gq-DREADD-mediated activation of these neurons/cells decreases food intake in mice (Adriaenssens et al., 2019). While these data indicate that Gipr is located on hypothalamic neurons that control feeding behavior, these Gipr-expressing neurons/cells most likely also express other factors that affect food intake. Hence, it remains unclear whether CNS Gipr signaling is of relevance for energy metabolism control in general and for the metabolic effects of GIP-based pharmacotherapies specifically. The aim of our studies is to assess the role of CNS Gipr in the systemic regulation of body weight, food intake, energy expenditure, and glucose metabolism. We show that mice with CNS deletion of murine (m)Gipr (nestin cre+/− mGiprflx/fl) and also humanized (h)GIPR knockin mice with conditional CNS deletion of hGIPR (nestin cre+/− hGIPRflx/flx) phenocopy global germline Gipr KO mice with respect to lower body weight and improved glucose metabolism upon HFD feeding. The lower body weight of CNS-mGipr KO mice and of CNS-hGIPR KO mice is accompanied by decreased food intake without changes in energy expenditure. Consistent with localization of Gipr in hypothalamic nuclei linked to control of appetite (Adriaenssens et al., 2019), we show that acute central and peripheral administration of fatty acyl-GIP increases cFOS neuronal activity in key hypothalamic feeding centers and that this coincides acutely and chronically with decreased body weight, food intake, and blood glucose. Chronic central (intracerebroventricular, i.c.v.) and peripheral (subcutaneous, s.c.) treatment with fatty acyl-GIP improves body weight and food intake in DIO WT mice, but this effect is absent upon i.c.v. fatty acyl-GIP treatment and blunted upon s.c. acyl-GIP treatment in CNS-Gipr KO mice. Also, the superior metabolic effects of unimolecular GLP-1/GIP dual-agonism relative to treatment with GLP-1 alone are extinguished in CNS-Gipr KO mice. In summary, our data reveal new roles for CNS Gipr signaling in control of energy metabolism and indicate that central Gipr signaling is essential for the anorectic effect of GIPR agonism and the metabolic benefits of dual GLP-1/GIP agonists. RESULTS Mice with CNS-specific deletion of mGipr are protected from diet-induced obesity and glucose intolerance To evaluate the role of CNS Gipr signaling for systemic energy metabolism control, we generated mice in which mGipr is deleted in the CNS by crossing mGiprflx/flx mice (Ussher et al., 2018) with mice that express the cre recombinase under control of the nestin promoter. Consistent with the phenotype of germline global Gipr KO mice (Miyawaki et al., 2002), CNS-mGipr KO mice showed lower body weight relative to WT control mice when chronically fed with an HFD (Figure 1A). Consistent with this, body fat, but not lean tissue mass, was decreased in CNS-mGipr KO mice (Figures 1B and 1C). CNS-mGipr KO mice exhibited reduced food intake (Figure 1D) with unchanged assimilated energy per gram eaten food (Figure 1E) and increased locomotor activity (Figure 1F) without transcriptional changes in hypothalamic Npy, Agrp, Pomc, or Cart (Figure 1G). No changes were observed in total energy expenditure, resting metabolic rate (Figures 1H and 1I), or expression of genes related to thermogenesis in brown adipose tissue (BAT) (Figure 1J). Also, substrate utilization (Figure 1K) and plasma levels of triglycerides and cholesterol (Figures 1L and 1M) were unchanged. CNS-mGipr KO mice showed improved glucose tolerance (Figures 1N and 1O) and decreased HbA1c (Figure 1P) without differences in fasting levels of blood glucose (Figure 1Q), but lower plasma levels of insulin (Figure 1R) and improved